Consolidated Financial Results for the Fiscal Year Ended July 31, 2025 Plans for the Fiscal Year Ending July 31, 2026 Mid-Term Plan 2026 Progress
September 25, 2025
Pharma Foods International Co., Ltd.
Note : This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.
Key Messages for Today
For the fiscal year ended July 31, 2025, net sales increased while
operating income decreased
Revenue increased in our functional materials sales and e-commerce businesses; however, operating profit declined due to higher advertising expenses, R&D investments for new projects (pharmaceuticals, textiles, and agriculture), and investments related to our Expo participation.
For the fiscal year ending July 2026, we expect revenue to increase, while operating profit is projected to decline.
While steadily achieving revenue of ¥68.0 billion through the growth of our existing businesses, we will continue strategic investments in creating new value, including the textiles and agriculture businesses as well as M&A initiatives.
Regarding the "New Value Creation 1K Project" outlined in our Mid-Term Plan 2026, we will maintain our commitment to achieving ¥100 billion in net sales in the fiscal year ending July 2026.
１．FY2025 Results and FY2026 Forecast
２．Initiatives of the "New Value Creation 1K Project"FY2025 Results Highlights ￥65,260M
YoY：105%
￥2,367MNet sales：Increased
Operating Profit：
Decreased
YoY：47%
￥368MNet Income Attributable to Parent
YoY：12%
(Million Yen) | FY2025(A) | FY2024(A) | Change | % | |
Net Sales | 65,260 | 62,147 | 3,113 | 5% | |
Operating Profit | 2,367 | 5,113 | -2,746 | -53% | |
Ordinary Income | 2,553 | 5,249 | -2,696 | -51% | |
Net Income Attributable to Parent | 368 | 3,205 | -2,837 | -88% | |
(Yen) | FY2025(A) | FY2024(A) | Change | % | |
EPS | 12.8 | 112.7 | -99.9 | -88% | |
Year-End Dividend per share | 25 | 25 | - | - | |
Operating Profit Change Factors by Segment - FY2025.A
BtoB：Sales of functional materials performed strongly (120% YoY), while the pharmaceutical
contract manufacturing business declined, achieving 70% of the previous year, resulting in lower profit
BtoC：E-commerce sales increased (108% YoY); however, higher advertising expenses (119% YoY) led to a decline in profit
Biomedical：R&D investments are ongoing to develop new antibody pharmaceutical candidates
5,113 (Unit：Million Yen)
▲325
▲1,622
▲105
2,367
▲693
FY24(A) BtoB BtoC Biomedical Others*1 FY25(A)
Adjustments*2
*1： "Others" includes segments outside the reportable segments, including fund management.
*2： "Adjustments" consist of corporate-wide expenses, including G&A, and depreciation/amortization.